Preview

Nephrology (Saint-Petersburg)

Advanced search

The role of bone metabolism regulators sclerotin and osteoprotegerin in the development of cardiovascular complications in the late stages of chronic kidney disease

https://doi.org/10.36485/1561-6274-2021-25-6-63-70

Abstract

BACKGROUND. Cardiovascular complications caused by vascular calcification in chronic kidney disease (CKD) are closely related to disorders of bone and mineral metabolism, the mechanisms of which require further study.

THE AIM: to clarify the role of the regulatory proteins of bone metabolism of sclerostin and osteoprotegerin in the processes of vascular calcification and the development of cardiovascular complications in CKD.

PATIENTS AND METHODS. 110 patients with stage 3-5D CKD (67 men) were examined. Median age is 47.0 (23.0-68.0) years. Osteoprotegerin (OPG), sclerostin, intact parathyroid hormone (IPTG), troponin I in blood serum were determined using commercial kits "Enzyme-linked Immunosorbent Assay Kit for Sclerostin" ("Cloud-Clone Corp.", USA) and commercial kits "ELISA kit" ("Biomedica" (Austria) by enzyme immunoassay (ELISA). Echocardiography with Dopplerography was performed on the device "ALOKA 4000" ("Toshiba", Japan). The left ventricular myocardial mass index (LVMI) and peak systolic blood flow velocity in the aortic arch (Vps, peak systolic velocity) were determined to quantify hemodynamic changes indirectly indicating the state of the aortic vascular wall.

RESULTS. Analysis of the ratios of the calculated glomerular filtration rate (EGFR), IMLJ, Vps, OPG, and sclerostin showed that a decrease in excretory kidney function is accompanied by an increase in the concentrations of OPG and sclerostin in the blood serum. At the same time, there is an increase in IMLJ and Vps. During the correlation analysis, it was shown that the level of OPG was positively correlated with the level of sclerostin and negatively with the level of iPTG.

CONCLUSION. In our study, we obtained data confirming the interactive interaction between the vascular and bone systems. Morphogenetic proteins-inhibitors of bone metabolism (sclerostin and OPG) play a significant role in the defeat of the cardiovascular system in patients with CKD, as they promotes the development of vascular calcification.

About the Authors

F. U. Dzgoeva
North Ossetian State Medical Academy
Russian Federation

Prof. Fatima U. Dzgoeva - MD, PhD, DMedSci, professor, Department of Internal Medicine № 5.

362040, Republic of North Ossetia-Alania Vladikavkaz, Pushkinskaya 40, Phone: +7(918)822-83-45



O. V. Remizov
North Ossetian State Medical Academy
Russian Federation

Prof. Oleg V. Remizov - MD, PhD, DMedSci, Department of Radiology with radiotherapy and oncology, professor.

362040, Republic of North Ossetia-Alania, Vladikavkaz, Pushkinskaya 40, Phone: 7(867)530397



V. Kh. Botsieva
North Ossetian State Medical Academy
Russian Federation

Victoria H. Botsieva - postgraduate student, Department of Biochemistry.

362040, Republic of North Ossetia-Alania,Vladikavkaz, Pushkinskaya 40, Phone: +7(928)857-33-55



N. G. Malakhova
North Ossetian State Medical Academy
Russian Federation

Nina G. Malakhova - postgraduate student, Department of Obstetrics and Gynecology No. 1.

362040, Republic of North Ossetia-Alania,Vladikavkaz, Pushkinskaya 40, Phone: +7(988)8386237



Z. R. Ikoeva
North Ossetian State Medical Academy
Russian Federation

Zarina R. Ikoeva, postgraduate student, Department of Internal Medicine №5.

362040, Republic of North Ossetia-Alania,Vladikavkaz, Pushkinskaya 40, Phone: +7(918)8304719



V. G. Goloeva
North Ossetian State Medical Academy
Russian Federation

Victoria G. Goloeva - postgraduate student, Department of Internal Medicine №5.

362040, Republic of North Ossetia-Alania,Vladikavkaz, Pushkinskaya 40, Phone: +7(960)4015003



E. Yu. Gireyeva
North Ossetian State Medical Academy
Russian Federation

Associate Prof. Elena Yu. Gireeva - MD, PhD, Department of Internal Medicine №5.

362040, Republic of North Ossetia-Alania,Vladikavkaz, Pushkinskaya 40, Phone: +7(928)4972808



A. E. Gurina
North Ossetian State Medical Academy
Russian Federation

Associate prof. Alla E. Gurina - MD, PhD, Department of Biochemistry, Head of Department.

362040, Republic of North Ossetia-Alania,Vladikavkaz, Pushkinskaya 40, Phone: +7(918)8258355



L. V. Tsallagova
North Ossetian State Medical Academy
Russian Federation

Larisa V. Tsallagova - MD, PhD, DMedSci, Department of Obstetrics and Gynecology No 1, Head of Department.

362040, Republic of North Ossetia-Alania,Vladikavkaz, Pushkinskaya 40, Тел.: +7(918)8278686



References

1. Pereira L, Frazao JM. The bone-vessel axis in chronic kidney disease: An update on biochemical players and its future role in laboratory medicine. Clin Chim Acta 2020;508:221-227. doi: 10.1016/j.cca.2020.05.02

2. Thompson B, Towler D. Arterial calcification and bone physiology: role of the bone-vascular axis. Nat Rev Endocrinol 2012;8:529-543. https://doi.org/10.1038/nrendo.2012.36

3. Frye MA,Melton LJ, Bryant SC et al. Osteoporosis and calcification of the aorta. Bone Miner 1992;19:185-194

4. London GM, Marchais SJ, Guerin AP et al. Association of bone activity, calcium load, aortic stiffness, and calcifications in ESRD. JAm Soc Nephrol 2008;19:1827-1835

5. Sieklucka B, Domaniewski T, Zieminska M et al. Correlation between OPG/RANKL/RANK axis, vitaminD status, PTH and vascular calcification in the adenin-indused model of chronic kidney Disease. Nephrology Dialysis Transplantation 2020;35: Supplement, gfaa142.P0690. doi: 10.1093/ndt/gfaa142.P0690

6. Dzgoeva FU, Sopoev MJ, Salamova EE et al. Osteoprote-gerin and RANKL: role in the development of cardiovascular complications in patients with end-stage renal failure receiving hemodialysis. Nephrology (Saint-Petersburg) 2017;21(5):28-35. (In Russ.)

7. Lukichev BG, Karunnaya AV, Rumyantsev AS. Indoxyl sulphate at chronic kidney disease. Nephrology (Saint-Petersburg) 2014;18(1):25-32. (In Russ.) https://doi.org/10.24884/1561-6274-2014-18-1-20-24

8. Dai L, Qureshi AR, Witasp A et al. Early vascular ageing and cellular senescence in chronic kidney disease. Comput Struct Biotechnol J 2019;17:21-729. https://doi.org/10.1016/j.csbj.2019.06.015

9. Kobayashi X Uehara S, Udagawa N et al. Regulation of bone metabolism by Wnt signals. J Biochem 2016;159:387-392

10. Kazuhiro Maeda, Yasuhiro Kobayashi, Masanori Koide et al. The Regulation of Bone Metabolism and Disorders by Wnt Signaling. Int J Mol Sci 2019; 20(22): 5525. https://doi.org/10.3390/ijms20225525

11. Drechsler C, Evenepoel P, Vervloet MG et al. NECOSAD Study Group. High levels of circulating sclerostin are associated with better cardiovascular survival in incident dialysis patients: results from the NECOSAD study. Nephrol Dial Transplant 2015;30(2):288-293. doi: 10.1093/ndt/gfu301

12. Stavrinou E, Sarafidis P, Loutradis C et al. Associations of serum sclerostin and DKK-1protein with future cardiovascular events and mortality in hemodialysis patients: a prospective cohort study. Nephrology Dialysis Transplantation 2020;35, Supplement, gfaa142.P1252. doi: 10.1093/ndt/gfaa142.P1252

13. Stavrinou E, Sarafidis P, Koumaras C et al. Increased Sclerostin, but Not Dickkopf-1 Protein, Is Associated with Elevated Pulse Wave Velocity in Hemodialysis Subjects. Kidney Blood Press Res 2019; 44(4): 679-689. doi. 10.1159/000501205

14. Claes KJ, Viaene L, Heye S et al. Sclerostin: another vascular calcification inhibitor? J Clin EndocrinolMetab 2013;98:3221-3228. doi: 10.1093/ndt/gfx152.SP558

15. Pelletier S, Dubourg L, Carlier MC et al. The relation between renal function and serum sclerostin in adult patients with CKD. Clin J Am Soc Nephrol 2013;8:819-823. doi: 10.2215/CJN.07670712

16. Thambiah S, Roplekar R, Manghat P et al. Circulating sclerostin and Dickkopf-1 (DKK1) in predialysis chronic kidney disease (CKD): relationship with bone density and arterial stiffness. Calcif Tissue Int 2012; 90: 473-480. https://doi.org/10.1007/s00223-012-9595-4

17. De Mare A, Maudsley S, Azmi A et al. Sclerostin as regulatory molecule in vascular media calcification and the bone-vascular axis. Toxins (Basel) 2019;11:428. https://doi.org/10.3390/toxins11070428

18. Wu J, Li X, Gao F et al. Osteoprotegerin SNP associations with coronary artery disease and ischemic stroke risk: a meta-analysis. Biosci Rep 2020;40(10):BSR202021. doi: 10.1042/BSR20202156

19. Rochette L, Meloux A, Rigal E et al. The Role of Osteoprotegerin in Vascular Calcification and Bone Metabolism: The Basis for Developing New Therapeutics. Calcif Tissue Int 2019;105:239-251. doi: 10.1007/s00223-019-00573-6

20. Ozaki Y Koide M, Furuya Y et al. Treatment of OPG-defi-cient mice with WP9QX a RANKL-binding peptide, recovers alveolar bone loss by suppressing osteoclastogenesis and enhancing osteoblastogenesis. PLoS One 2017;12:e0184904. https://doi.org/10.1371/journal.pone.0184904

21. Ozaki Y Koide M, Furuya Y et al. Treatment of OPG-defi-cient mice with WP9QX a RANKL-binding peptide, recovers alveolar bone loss by suppressing osteoclastogenesis and enhancing osteoblastogenesis. PLoS One 2017;12:e0184904. doi: 10.1371/journal.pone.0184904

22. Hobson S, Arefin S, Kublickiene K et al. Senescent cells in early vascular ageing and bone disease of chronic kidney disease— a novel target for treatment. Toxins (Basel) 2019;11:82. https://doi.org/10.3390/toxins11020082

23. Kaesler N, Babler A, Floege J, Kramann R. Cardiac Remodeling in Chronic Kidney Disease. Toxins 2020;12(3):161-169. doi.org/10.3390/toxins12030161

24. Smirnov AV, Rumyantsev AS. Bone tissue function and structure under normal and pathological condition. Message II. Nephrology (Saint-Petersburg) 2015;19(1):8-17. (In Russ.)

25. Ozaki X Koide M, Furuya Y et al.Treatment of OPG-deficient mice with WP9QX a RANKL-binding peptide, recovers alveolar bone loss by suppressing osteoclastogenesis and enhancing osteoblastogenesis. PLoS One 2017;12(9):e0184904. doi: 10.1371/journal.pone.0184904. PMID: 28937990; PMCID: PMC5609750.

26. Palmer SC, Teixeira-Pinto A, Saglimbene V et al. Association of Drug Effects on Serum Parathyroid Hormone, Phosphorus, and Calcium Levels With Mortality in CKD: A Metaanalysis. Am J Kidney Dis 2015;66(6):962-971. doi: 10.1053/j.ajkd.2015.03.036

27. Nam X Lee S, Kim HW et al. Serum levels of osteopro-tegerin are associated with obesity in chronic kidney disease. Nephrology Dialysis Transplantation 2020; 35, Supplement_3, gfaal 42.P0930. doi: 10.1093/ndt/gfaal42.P0930

28. Delanaye P, Paquot F, Bouquegneau A et al. Sclerostin and chronic kidney disease: the assay impacts what we (thought to) know. Nephrol Dial Transplant 2018;33(8):1404—10. doi: 10.1093/ndt/gfx282


Review

For citations:


Dzgoeva F.U., Remizov O.V., Botsieva V.Kh., Malakhova N.G., Ikoeva Z.R., Goloeva V.G., Gireyeva E.Yu., Gurina A.E., Tsallagova L.V. The role of bone metabolism regulators sclerotin and osteoprotegerin in the development of cardiovascular complications in the late stages of chronic kidney disease. Nephrology (Saint-Petersburg). 2021;25(6):63-70. (In Russ.) https://doi.org/10.36485/1561-6274-2021-25-6-63-70

Views: 768


ISSN 1561-6274 (Print)
ISSN 2541-9439 (Online)